Full-Time
HR Business Partner 2
Posted on 6/22/2025
IQVIA
10,001+ employees
Analytics and research for life sciences
No salary listed
Senior, Expert
Bengaluru, Karnataka, India
- Bachelor's Degree
- Extensive knowledge of local and relevant employment legislation
- Strong computer skills, including Microsoft Office applications and HRIS applications
- Excellent problem solving, judgment and decision making skills
- Strong verbal and written communication skills
- Good presentation skills
- Good influencing skills
- Good coaching and counseling skills
- Very high degree of discretion and confidentiality
- Strong attention to detail
- Ability to multi-task, prioritize and plan routine activities
- Good ability to work in a matrix environment
- Ability to establish and maintain effective working relationships with coworkers, managers and clients
- Professional HR accreditation in progress
- Develop strong and effective team relationships with HR specialist functions/Centers of Excellence, e.g., HRPSC, Finance PSC
- Support line managers in the process of new employee orientation where appropriate
- Conduct ad hoc reviews as directed and propose recommendations in handling employment legislation, compliance, HR systems, practices and procedures and, with guidance, provide support and education to line management
- Participate as assigned, with minimal supervision, in working with senior HR team members in the day-to-day development and implementation of new local and global HR initiatives
- Work with more experienced HR team members on organizational effectiveness and HR partnering change management efforts associated with reorganizations, mergers/acquisitions and transfers to ensure compliance to local legislation
- Provide reports and analyses as requested by senior management
- Support line managers in the recruitment and selection process where appropriate
- Operate as first point of contact for HR-related queries and work in conjunction with senior members of the HR team and line management on issues.
- Minimum 7 years experience within an HR function as a generalist or combination of generalist and specialist experience
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their services utilize big data and technology to create connections that enhance healthcare insights. The main product, IQVIA Connected Intelligence™, helps clients quickly gather insights to speed up the development and marketing of new medical treatments, which can lead to better healthcare outcomes. What sets IQVIA apart from its competitors is its strong focus on patient privacy, employing various technologies to protect individual data. The company's goal is to support biotech, pharmaceutical, and medical device companies, as well as researchers and healthcare organizations, in understanding diseases and improving treatment options.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA's Med-R1 8B LLM aids healthcare professionals in interpreting complex clinical data.
- Winning the 2025 MedTech Breakthrough Award boosts IQVIA's reputation in patient engagement.
- Recognition in IDC MarketScape's 2024 assessment highlights IQVIA's leadership in decentralized trials.
What critics are saying
- Public scrutiny from Vimergy's campaign may impact IQVIA's reputation and client relations.
- CAR T-cell therapy access disparities in Europe could lead to regulatory pressures on IQVIA.
- $2 billion senior notes offering may increase financial risk if market conditions worsen.
What makes IQVIA unique
- IQVIA leverages AI-powered analytics to enhance clinical research and healthcare solutions.
- The company is a leader in protecting individual patient privacy with advanced technologies.
- IQVIA's global presence spans over 100 countries, offering extensive domain expertise.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...
<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>
Research Triangle Park, N.C., - June 16, 2025 - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program.
New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication
NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%